Background There has been no single standard-of-care treatment of patients with advanced/metastatic soft tissue sarcoma (STS). This study was designed to understand patient and oncologist preferences in the advanced/metastatic setting. Methods Adult patients diagnosed with STS and oncologists treating patients with STS completed discrete choice experiment surveys. Study participants chose between pairs of hypothetical treatment profiles for advanced STS characterized by varying levels of overall survival (14, 20, or 26 months), progression-free survival (3, 5, or 7 months), objective tumor response rate (12, 18, or 26%), risk of hospitalization due to side effects (12, 30, or 46%), and days/month to administer treatment (1, 2, or 4 days). A hierarchical Bayes model was used to estimate preferences and relative importance of attributes. Results Seventy-six patients (23.7% male, mean age 52.8 years) and 160 oncologists (73.8% male, mean 16.9 years in practice) completed the surveys. Among patients, overall survival had the highest relative importance (39.5%, standard deviation [SD] 18.2%), followed by response rate (21.2%, SD 10.4%), and hospitalization (19.8%, SD 12.5%). Among oncologists, overall survival had the highest relative importance (44.6%, SD 16.0%), followed by hospitalization (18.4%, SD 8.3%). Conclusions Both patients with STS and oncologists preferred a treatment that maximizes the life of patients while avoiding hospitalizations.
Introduction
Soft tissue sarcoma (STS) is a heterogeneous group of cancers that originate in the soft tissues of the body, such as muscles, fat, nerves, tendons, and blood vessels. STS is relatively rare, accounting for approximately 1% of all cancers diagnosed annually in the US [1] . More than 50 histologic subtypes of STS have been identified, each with distinct underlying biology, natural history, and response to treatments [2] .
While there has historically been no single standard of care for advanced, unresectable, or metastatic STS [3] , chemotherapy (single agents or combination regimens) is widely used and new standards have more recently emerged. Available data from randomized clinical trials demonstrate an advantage of chemotherapy compared with best supportive care in terms of palliation of symptoms and improvement of survival for patients with advanced STS [4] . However, in the last few decades there have been few advancements in the progress that chemotherapy achieves for altering treatment outcomes of patients with metastatic disease [5, 6] . More recently, a number of targeted therapies, such as olaratumab, pazopanib, and imatinib, have been approved for the treatment of STS by the US FDA, and others, such as sunitinib, mammalian target of rapamycin (mTOR) inhibitors (e.g. sirolimus, temsirolimus, and everolimus), bevacizumab, and palbociclib, have shown promising results in patients with certain histologic types of advanced or metastatic STS [2, 7] .
Because the treatment of patients with advanced STS is complex, there is a need to understand which factors are prioritized by patients and oncologists in their decisionmaking process. The choice between treatment regimens may be influenced by many factors, including patient clinical factors and treatment-specific factors (such as effectiveness and safety). While there are many studies on cancer patients' preferences regarding cancer treatment [8] [9] [10] [11] [12] , only one study has been identified that focuses on STS patients, but that study did not investigate preferences for characteristics or outcomes of chemotherapy treatment [13] .
To address this gap in knowledge, two discrete choice experiment (DCE) surveys were separately administered to adult patients and oncologists to assess their preferences regarding advanced STS treatment characteristics and outcomes (overall survival, progression-free survival, objective tumor response rate, risk of hospitalization due to side effects during the treatment period, and convenience of the treatment as measured by number of days per month to administer chemotherapy treatment in a clinic setting). The relative importance of these characteristics, as well as the willingness to trade-off between them, were also estimated.
Methods

Study Participants
Eligible patients were at least 18 years of age, had a diagnosis of STS, were currently receiving or had received chemotherapy for STS within the past 2 years, and had no diagnosis of osteosarcoma, gastrointestinal stromal tumor (GIST), or Kaposi's sarcoma at the time of the survey. The requirement for chemotherapy treatment for STS within the past 2 years was used to ensure familiarity with the experience of chemotherapy treatment. Recruitment was conducted through physician referrals from physicians who treat patients with sarcoma, as well as through a study announcement (disseminated via website announcement, Facebook, and by email outreach) by a patient advocacy group. Participants recruited through the online announcement did not receive compensation for their time to complete the survey to avoid risk of falsely self-reporting themselves as sarcoma patients to receive reimbursement. Eligible providers were oncologists who currently prescribed chemotherapy treatment for adult patients with STS in the US. No quotas were imposed based on sex, geographic region, or years in practice. Oncologists were recruited from a panel of oncologists in the US (Lightspeed Health, New York, NY, USA), whose verification process involves matching the panelist's name, license number, and work contact information to public databases, email address and diploma verification, and contacting panelists on the public phone number of the doctor's practice. All study procedures were approved by the Western Institutional Review Board, Puyallup, WA, USA. Patient-level data are not publicly available upon request to maintain participant confidentiality. As part of the informed consent for the survey, participants were informed that survey responses would be reported and published only in summary form.
Survey Design
Two separate DCE surveys were administered online to patients and oncologists (providers), respectively. The DCE study design is a rigorous method for eliciting preferences and quantifying trade-offs without directly asking the respondents about their preferences for the treatment of advanced/unresectable STS. DCEs are based on the random utility theory proposed by Thurstone [14] and extended to multiple comparisons by McFadden [15, 16] . Directly asking respondents about their preferences through ratings-based assessments, where they are asked to rate the importance of each attribute on a Likert scale (e.g. 0-10) or to rank different attributes, have a number of limitations, including the inability to differentiate between attributes if respondents rate all of them as very important, differences in how individuals value a number on a scale, and no relative importance information (i.e. ranking may provide information about the order of preferences over attributes but not about their relative importance). A major advantage of the DCE study design is that it gives researchers control over the experimental factors used to generate the preference data, thus avoiding problems of confounding, correlation, insufficient variation, and unobserved variables common in the analysis of preference data obtained from directly observing respondents' real-world choices [17] .
After obtaining informed consent, general survey questions were asked (including patient or provider characteristics, and experience with STS), which were followed by the definition and description of relevant attribute terms used in the DCE exercise, and finally the DCE exercise. Patients recruited through physician referrals were compensated $50 for completing the patient survey. The DCE exercise assessed respondent preferences by presenting a series of choices between pairs of hypothetical treatment profiles for advanced/unresectable STS, which were characterized using a common set of attributes relevant to STS but with differences in the levels of one or more attributes. The following common set of key attributes for both patient and provider surveys were included, based on an assessment of the clinical trial data supporting the key treatment options for first-line chemotherapy treatment in advanced or metastatic STS [18] [19] [20] : overall survival, progressionfree survival, objective response rate, hospitalizations due to side effects during the treatment period, and convenience of the treatment as measured by number of days per month to administer chemotherapy treatment in a clinic setting. Table 1 presents a summary of the attributes and levels that were selected for use in the DCE exercises based on these clinical trials.
An experimental design [21] was constructed using Sawtooth Software SSI Web 8.4.8 (Sawtooth Software Inc., Provo, UT, USA) [22] . The efficiencies for parameter estimation ranged between 93.1 and 99.7%. Fifty-three blocks were created and respondents were randomly assigned one block. Each block contained 12 choice exercises, two of which were included to test for consistency of individual responses: a test-retest exercise and a dominant alternative test; these two choice exercises were not used in the estimation of preference weights for the attributes and levels. The test-retest exercise tested that subjects who preferred Treatment A to Treatment B at one point in the sequence of choice exercises should also prefer Treatment A to Treatment B at any subsequent point. The dominant alternative test determined whether respondents sufficiently understood the evaluation task to indicate a preference for an unambiguously better treatment profile (see electronic supplementary Fig. 1 for the dominant alternative test). The minimum target sample size for each of the participant and patient surveys, based on the rule of thumb proposed by Johnson and Orme [23, 24] , was estimated to be 75 participants.
The patient and oncologist surveys were pre-tested with five oncologists who provided comments about the clarity of the language, relevance of the attributes and levels, and interpretation of the DCE survey questions. The final surveys incorporated the revisions based on the survey pretest. An example scenario presented to patients and providers is presented in Fig. 1. 
Statistical Analysis
The primary analyses were conducted among the participants who passed the dominant alternative test. General survey questions were analyzed using descriptive statistics: mean and standard deviation (SD) for continuous variables, and number and proportion for categorical variables. Respondents' preferences from the DCE portion of the survey were analyzed using a hierarchical Bayes model, where the probability of each respondent choosing a particular alternative given their preferences was governed by a logistic regression model whose independent variables are the attribute levels (effects coded), and, at a higher level, respondents' preferences were described by a multivariate normal distribution. Preference weights associated with different attribute levels, relative importance of each attribute in the overall sample (as well as in subgroups), and willingness to trade-off between treatment attributes, were estimated for each survey. The relative importance of an attribute was calculated as the range of parameter estimates for the given attribute divided by the sum of ranges of parameter estimates for all attributes. For a given attribute, the relative importance calculation was performed in two steps. First, the importance weight for each individual was calculated, and, second, the individual relative importance weights were averaged across the entire population. The willingness to trade-off estimates between attributes A and B quantify the number of units of B that would leave utility unchanged if traded for one unit of A. It is calculated as the ratio of the range of the preference weights of attribute A over the range of levels of attribute A, divided by the analogous ratio for attribute B. Analyses of general survey questions were performed using SAS 9.4 (SAS Institute, Cary, NC, USA). DCE analyses were performed using Sawtooth Software SSI Web 8.4.8 (Sawtooth Software Inc.) and the CBC/HB package version 5.0 (Sawtooth Software Inc.). Bayesian 95% credible intervals were calculated at the population mean utility level to identify estimated preference weights that were different from zero [25] .
Subgroup analyses were conducted to investigate if preferences regarding specific treatment attributes varied by participant characteristics. Hierarchical Bayes models with a subgroup indicator were estimated, and the indicators were used to conduct statistical tests for the preference weights between subgroup categories. In addition, pairwise t tests were performed to compare the relative importance of attributes between subgroup categories. Three subgroup analyses for patients were conducted by stratifying by sex, age, and metastatic status; for providers, two subgroup analyses were conducted by stratifying by sex and years of experience. In addition, sensitivity analyses were performed to confirm the internal validity of the results. The sensitivity analyses included fitting a hierarchical Bayes model to the subpopulation defined by respondents who also passed the test-retest test, and fitting a hierarchical Bayes model to all respondents who provided a complete response to the survey (regardless of whether they passed the dominant alternative or test-retest test).
Results
Patient and Provider Characteristics
Patient Characteristics
A total of 78 eligible patients completed the study; 76 passed the dominant alternative test and were included in the primary analyses. As demonstrated in Table 2 , the majority of patients were female (76.3%), White or Caucasian (86.8%), with a mean age of 52.8 years. Approximately one-third of patients had a bachelor's degree (30.3%), and 26.3% had a master's degree or higher. The average time since the first STS diagnosis was 4.1 years, and most patients reported having metastatic disease at the time of the survey (72.4%). The majority of patients reported having no limitations in their walking ability and some limitations in physically demanding activities (48.7%). The most commonly reported locations of the first appearance of STS were the uterus/womb (28.9%), legs (25.0%), and abdomen (23.7%). The most commonly used chemotherapy regimens for STS reported were doxorubicin alone (50.0%), AIM (doxorubicin, ifosfamide, mesna; 28.9%), and pazopanib (27.6%); patients were allowed to select multiple regimens. The majority of patients had a previous hospitalization due to a side effect during chemotherapy treatment (56.6%). When directly asked to rate the importance of each attribute on a scale from 0 to 10 (with 10 being extremely important), on average patients rated all attributes as being very important (attribute importance range 7.8-8.4); these responses did not allow to differentiate between attributes.
Provider Characteristics
A total of 206 oncologists completed the study survey; 160 passed the dominant alternative test and were included in the primary analyses. Most providers were male (73.8%), with 41.3% in private practice (Table 3 ). Providers' current practice locations included all regions of the US, with slightly more locations in the South (35.0%). The mean time practicing oncology for the participating physicians was 16.9 years (SD 7.9 years). When directly asked to rate the importance of each attribute on a scale from 0 to 10 (with 10 being extremely important), on average providers rated all attributes as being very important (attribute importance range 7.6-7.9); these responses did not allow to differentiate between attributes.
Preference Results
Patient Preferences
Overall survival at the level of 26 months had the largest positive preference weight estimate among patients, followed by objective response rate at the level of 26% (both estimates were significantly different from 0 with 95% probability). Overall survival of 14 months had the largest negative preference weight, followed by risk of hospitalization due to side effects during the treatment period at the level of 12% (Fig. 2a) [both estimates significantly different from 0 with 95% probability]. Preference weights were rescaled as zero-centered differences [19] . Overall survival had the largest range of average preference weights, and was therefore the most important attribute for patients' treatment preferences (39.5% relative importance, SD 18.2%). Overall survival was followed by objective response rate (21.2%, SD 10.4%) and the risk of hospitalization due to side effects during the treatment period (19.8%, SD 12.5%) based on the range of the tested attribute levels in the DCE. Progression-free survival (11.0%, SD 3.7%) and number of days per month to administer treatment (8.4%, SD 4.3%) were the least important attributes (Fig. 3a) . For a 1-month increase in overall survival, patients were willing to tradeoff a 2.2 percentage point decrease in objective response rate, a 6.0 percentage point increase in hospitalization risk, a 1.2-month reduction in progression-free survival, and an additional 1.4 days/month to administer treatment (Table 4) .
Oncologist Preferences
Overall survival at the level of 26 months had the largest positive preference weight estimate for oncologists, followed by risk of hospitalization due to side effects during the treatment period at the level of 12% (Fig. 2b) [both estimates significantly different from 0 with 95% probability].
Based on the range of tested attributed levels in the DCE, overall survival was the most important attribute for oncologists' treatment preferences (44.6% relative importance, SD 16.0%) because it had the largest range of estimated average preference weights. This was followed by the risk of hospitalization due to side effects during the treatment period (18.4%, SD 8.3%), and progression-free survival (16.5%, SD 7.8%). Objective response rate (10.6%, SD 7.0%) and number of days per month to administer treatment (9.9%, SD 9.5%) were the least important attributes (Fig. 3b) . For a 1-month increase in overall survival, oncologists were willing to trade-off an 8.9 percentage point increase in hospitalization risk, a 2.1-month reduction in progression-free survival, a 13.1 percentage point decrease in response rate, and an additional 4.7 days/month to administer treatment (Table 4 ).
Preference Results by Subgroup
Patient Subgroups
For both female (n = 58) and male (n = 18) patients, overall survival was the most important attribute (females: 41.0% relative importance, SD 17.8%; males: 33.6%, SD 17.2%).
The results by sex in regard to order of preferred attributes were consistent with those obtained for the overall sample of patients. No statistical comparisons were performed because of limited sample size. For patients aged 55 years and younger (n = 38) and those over the age of 55 years (n = 38), overall survival was the most important attribute (younger: 37.9% relative importance, SD 16.5%; older: 38.7%, SD 16.4%). Younger patients placed significantly less importance on the risk of hospitalization than patients aged over 55 years (13 For patients with self-reported metastatic disease (n = 55), as well as those without metastatic disease at the time of the survey (n = 19), overall survival was the most important attribute (negative status: 43.0% relative importance, SD 20.7%; positive status: 38.4%, SD 18.0%). For patients who did not have metastatic disease, objective response rate was the next important attribute (19.2%, SD 9.6%); the rest of the attributes were assigned a similar, lower importance. For patients with self-reported metastatic disease, both objective response rate (21.5%, SD 10.6%) and the risk of hospitalization (21.1%, SD 12.0%) had a similar importance. No statistical comparisons were performed because of the limited sample size. 
Oncologist Subgroups
Two respondents declined to answer the question about sex and were not included in this subgroup analysis. For male (n = 118) and female (n = 40) oncologists, overall survival was the most important attribute (males: 46.5% relative importance, SD 17.9%, females: 39.7%, SD 12.5%) and was significantly more important for males than females (p < 0.01). Males considered progression-free survival to be less important than females (males: 15.8% relative importance, SD 8.3%, females: 18.8%, SD 7.0%; p < 0.05). The results by sex were consistent with those obtained for the overall sample of oncologists.
Oncologists were grouped by years of experience (< 15 years practicing oncology [n = 52], at least 15 years but less than 20 years practicing oncology [n = 52], and at least 20 years practicing oncology [n = 56]). Overall survival was also the most important attribute for each group (49.9%, 45.2%, and 40.1%, respectively), with oncologists with < 15 years of experience assigning significantly more importance than those with at least 20 years of experience (p < 0.01). Progression-free survival and objective response rate had 16.8% and 12.4% relative importance, respectively, for oncologists with more than 20 years in practice. The results by years of experience were consistent with those obtained for the overall sample of oncologists.
Sensitivity Analyses
Sensitivity analyses for the subpopulation defined by respondents who also passed the test-retest test were consistent with those from the main analyses described above for the overall samples of patients and oncologists.
The sensitivity analysis for the population of patients who provided a complete response to the survey, regardless of whether they passed the dominant alternative or test-retest test, were also consistent with those from the primary analyses. For patients (n = 78), the hierarchical Bayes model showed that overall survival had the highest relative importance (38.0%, SD 17.9%), followed by objective response rate (20.7%, SD 9.8%) and risk of hospitalization due to side effects during the treatment period (19.7%, SD 11.7%). For oncologists (n = 206), the hierarchical Bayes model showed that overall survival had the highest relative importance (40.5%, SD 16.8%), followed by risk of hospitalization due to side effects during the treatment period (18.1%, SD 8.8%). . Each preference weight reflects the utility that a respondent associates with the corresponding attribute level. Positive weights are associated with high utility, whereas negative weights are associated with disutility. Within an attribute, the preference weights sum to 0. Attributes with a greater range of preference weights have a greater relative importance than attributes with a smaller range of preference weights. Bars denote standard errors of the part-worth utilities; * denotes the part-worth utility estimate is different from zero with 95% probability. SD standard deviation Fig. 3 Relative importance of treatment attributes-hierarchical Bayes model. a Relative importance for patients; b relative importance for providers. The relative importance of each treatment attribute is its relative contribution to the overall utility. For a given attribute, the relative importance calculation was performed in two steps: (1) for each respondent, the importance weight for a given attribute was calculated as the range of preference weights for the attribute for that respondent divided by the sum of ranges of preference weights for all attributes for that respondent; and (2) for a given attribute, the individual importance weights were averaged across the entire sample of respondents
Relative importance
Discussion
Overall survival was the most important attribute for both adults with STS and oncologists surveyed in this study. Risk of hospitalization due to side effects during the treatment period was also an important attribute for both patients and oncologists. The number of days per month to administer chemotherapy treatment had the lowest relative importance to both patients and oncologists. The order of relative importance of objective response rate and progression-free survival was different for patients and providers, suggesting that these factors may need to be included in patient-provider discussions about treatment options to ensure that patient preferences are understood. As the population of sarcoma patients is relatively small (sarcoma accounts for < 1% of all cancers diagnosed), oncologists may not routinely care for patients with this rare tumor. Therefore, these data may inform discussions around treatment selection, particularly in the first-line setting, where the chances of survival benefits are greatest. Keeping survival in mind as the ultimate goal may help facilitate patient-provider treatment decision making to find the treatment that is in accordance with patient preferences for their care. While for the overall patient sample objective response rate and risk of hospitalization generally had similar importance, younger patients and patients without metastatic disease at the time of survey completion may perceive their prognosis as better. Among these patients, objective response rate had numerically higher relative importance than risk of hospitalization. For subgroup analyses of provider preferences, the most important attributes remained the same.
The DCE study design is a rigorous method for eliciting preferences and quantifying trade-offs without directly asking the respondents about their preferences. However, this study was limited by self-reported data and could have been subject to recall biases and other self-reporting biases. Patients who participated in the online survey may not be representative of all patients with STS receiving chemotherapy in the US. For example, 56.6% of survey participants had a bachelor's degree or higher. Similarly, oncologists who participated in this study may not be representative of oncologists who are currently actively providing chemotherapy treatment for patients in the US with STS. In terms of oncologists' experience with treatment of adults with advanced STS, a high average number of treated adult patients with advanced STS in the past year (median of 30) was observed. It is possible that oncologists interpreted this question as the number of patients with sarcoma treated at their practice rather than treated personally by them. The provider survey focused on oncologists who prescribed chemotherapy for patients with STS, but did not require treatment of STS patients within the year before survey completion. Thus, some of the oncologists who participated in the survey may not have been actively prescribing chemotherapy treatment for STS patients at the time of survey completion. Furthermore, the DCE was a simplified hypothetical exercise designed to assess the relative importance of treatment attributes and levels. In reality, some of the presented combinations may not be observed, and other factors not included in the DCE may have an important role in decision making (e.g. comorbidities, family dynamics, insurance coverage/out of pocket costs).
Future research could focus on investigating other factors that may influence treatment decisions, such as the aforementioned family dynamics, caregiver burden, or costs. Future research may consider a larger comparative study to statistically test the differences between patients and providers; however, the challenges of recruiting a sufficient number of patients with a rare tumor would need to be addressed. At this time, these descriptive data may provide some hypotheses that could be tested in a larger, adequately powered comparative study. As newer treatments become available for patients diagnosed with sarcoma, this type of research may allow for the investigation of preferences among specific treatment alternatives, which would provide a clinically relevant regimen comparison, versus the attribute-level analysis that was the focus of the current study.
Conclusions
This study provided evidence about the preferences for advanced STS treatment among both adult patients diagnosed with STS and oncologists who treat patients with STS in the US. Patients and oncologists prefer treatments that maximize overall patient survival while avoiding hospitalizations, suggesting that overall survival should be prioritized for treatment decisions. Patient overall survival was the most important attribute regardless of patients' sex, age, or metastatic status, and regardless of sex or experience of oncologists.
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